دورية أكاديمية
Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment.
العنوان: | Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment. |
---|---|
المؤلفون: | Silvestre ALP; School of Pharmaceutical Sciences, UNESP-Sao Paulo State University, Rodovia Araraquara-Jau, km. 1, Araraquara, Sao Paulo 14800-903, Brazil., Oshiro-Júnior JA; Graduation Program in Pharmaceutical Sciences, State University of Paraiba, Campina Grande, Joao Pessoa, Brazil., Garcia C; School of Pharmaceutical Sciences, UNESP-Sao Paulo State University, Rodovia Araraquara-Jau, km. 1, Araraquara, Sao Paulo 14800-903, Brazil., Turco BO; School of Pharmaceutical Sciences, UNESP-Sao Paulo State University, Rodovia Araraquara-Jau, km. 1, Araraquara, Sao Paulo 14800-903, Brazil., da Silva Leite JM; Graduation Program in Pharmaceutical Sciences, State University of Paraiba, Campina Grande, Joao Pessoa, Brazil., de Lima Damasceno BPG; Graduation Program in Pharmaceutical Sciences, State University of Paraiba, Campina Grande, Joao Pessoa, Brazil., Soares JCM; School of Pharmaceutical Sciences, UNESP-Sao Paulo State University, Rodovia Araraquara-Jau, km. 1, Araraquara, Sao Paulo 14800-903, Brazil., Chorilli M; School of Pharmaceutical Sciences, UNESP-Sao Paulo State University, Rodovia Araraquara-Jau, km. 1, Araraquara, Sao Paulo 14800-903, Brazil. |
المصدر: | Current medicinal chemistry [Curr Med Chem] 2021; Vol. 28 (2), pp. 401-418. |
نوع المنشور: | Journal Article; Review |
اللغة: | English |
بيانات الدورية: | Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 9440157 Publication Model: Print Cited Medium: Internet ISSN: 1875-533X (Electronic) Linking ISSN: 09298673 NLM ISO Abbreviation: Curr Med Chem Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Saif Zone, Sharjah, U.A.E. : Bentham Science Publishers Original Publication: Schiphol, The Netherlands : Bentham Science Publishers, |
مواضيع طبية MeSH: | Nanoparticles* , Neoplasms*/drug therapy, Antibodies, Monoclonal/therapeutic use ; Biosimilar Pharmaceuticals ; Drug Delivery Systems ; Humans ; Micelles |
مستخلص: | Monoclonal antibodies carried in nanosystems have been extensively studied and reported as a promising tool for the treatment of various types of cancers. Monoclonal antibodies have great advantages for the treatment of cancer because their protein structure can bind to the target tissue; however, it has some challenges such as denaturation following heat exposure and extreme values of pH, temperature and solvents, the ability to undergo hydrolysis, oxidation and deamination and the formation of non-native aggregates, which compromise drug stability to a large extent. In addition to these characteristics, they suffer rapid elimination when in the blood, which results in a short half-life and the production of neutralizing antibodies, rendering the doses ineffective. These challenges are overcome with encapsulation in nanosystems (liposomes, polymer nanoparticles, cyclodextrins, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers and micelles) due to the characteristics of improving solubility, permeability, and selectivity only with tumor tissue; with that, there is a decrease in side effects beyond controlled release, which is critical to improving the therapeutic efficacy of cancer treatment. The article was divided into different types of nanosystems, with a description of their definitions and applications in various types of cancers. Therefore, this review summarizes the use of monoclonal antibodies encapsulated in nanosystems and the description of clinical studies with biosimilars. Biosimilars are defined as products that are similar to monoclonal antibodies which are produced when the patent for the monoclonal antibodies expires. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
فهرسة مساهمة: | Keywords: Drug delivery nanosystems; antibodies; biopharmaceuticals; biosimilars; cancer treatment; new therapy |
المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Biosimilar Pharmaceuticals) 0 (Micelles) |
تواريخ الأحداث: | Date Created: 20200123 Date Completed: 20210209 Latest Revision: 20210209 |
رمز التحديث: | 20240628 |
DOI: | 10.2174/0929867327666200121121409 |
PMID: | 31965938 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!